Vor Biopharma Inc.
VOR
$0.59
-$0.044-6.94%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -17.49% | -13.15% | -12.87% | -5.91% | -5.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.33% | -19.26% | -9.76% | 6.26% | 13.75% |
| Operating Income | -11.33% | 19.26% | 9.76% | -6.26% | -13.75% |
| Income Before Tax | -16.95% | 16.97% | 7.14% | -8.34% | -9.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.95% | 16.97% | 7.14% | -8.34% | -9.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.95% | 16.97% | 7.14% | -8.34% | -9.83% |
| EBIT | -11.33% | 19.26% | 9.76% | -6.26% | -13.75% |
| EBITDA | -11.80% | 19.64% | 10.02% | -6.08% | -13.03% |
| EPS Basic | -13.30% | 18.01% | 8.86% | -5.52% | 26.50% |
| Normalized Basic EPS | -13.31% | 17.99% | 8.84% | -5.52% | 26.52% |
| EPS Diluted | -13.30% | 18.01% | 8.86% | -5.52% | 26.50% |
| Normalized Diluted EPS | -13.31% | 17.99% | 8.84% | -5.52% | 26.52% |
| Average Basic Shares Outstanding | 3.22% | 1.27% | 1.89% | 2.66% | 49.45% |
| Average Diluted Shares Outstanding | 3.22% | 1.27% | 1.89% | 2.66% | 49.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
